Clinical Trial Update: A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study to determine the maximum tolerated dose of ASG-5ME in patients with castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ASG-5ME (ASG-5ME)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Prostate Neoplasms | Phase 1 | Status: COMPLETED